vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and SILVERCORP METALS INC (SVM). Click either name above to swap in a different company.
SILVERCORP METALS INC is the larger business by last-quarter revenue ($223.8M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). Over the past eight quarters, SILVERCORP METALS INC's revenue compounded faster (87.6% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Silvercorp Metals Inc. (Silvercorp) is a Canadian-based, China-focused precious metals company engaged in the acquisition, exploration, and development of silver-containing properties.
ESPR vs SVM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $223.8M |
| Net Profit | — | $-2.9M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | -1.3% |
| Revenue YoY | 143.7% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $223.8M | ||
| Q3 25 | $87.3M | — | ||
| Q2 25 | $82.4M | $72.2M | ||
| Q1 25 | $65.0M | — | ||
| Q4 24 | $69.1M | $172.5M | ||
| Q3 24 | $51.6M | $114.0M | ||
| Q2 24 | $73.8M | $60.0M | ||
| Q1 24 | $137.7M | — |
| Q4 25 | — | $-2.9M | ||
| Q3 25 | $-31.3M | — | ||
| Q2 25 | $-12.7M | $28.1M | ||
| Q1 25 | $-40.5M | — | ||
| Q4 24 | — | $42.1M | ||
| Q3 24 | $-29.5M | $28.0M | ||
| Q2 24 | $-61.9M | $13.2M | ||
| Q1 24 | $61.0M | — |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | 30.5% | ||
| Q3 24 | -31.0% | 30.7% | ||
| Q2 24 | 3.5% | 30.0% | ||
| Q1 24 | 52.5% | — |
| Q4 25 | — | -1.3% | ||
| Q3 25 | -35.9% | — | ||
| Q2 25 | -15.4% | 39.0% | ||
| Q1 25 | -62.2% | — | ||
| Q4 24 | — | 24.4% | ||
| Q3 24 | -57.2% | 24.5% | ||
| Q2 24 | -83.9% | 22.0% | ||
| Q1 24 | 44.3% | — |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | — |
| Total Assets | $465.9M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | — | ||
| Q2 25 | $-433.5M | — | ||
| Q1 25 | $-426.2M | — | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | — | ||
| Q2 24 | $-344.2M | — | ||
| Q1 24 | $-294.3M | — |
| Q4 25 | $465.9M | — | ||
| Q3 25 | $364.0M | — | ||
| Q2 25 | $347.1M | — | ||
| Q1 25 | $324.0M | — | ||
| Q4 24 | $343.8M | — | ||
| Q3 24 | $314.1M | — | ||
| Q2 24 | $352.3M | — | ||
| Q1 24 | $373.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $107.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $107.9M | ||
| Q3 25 | $-4.3M | — | ||
| Q2 25 | $-31.4M | $40.0M | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $-35.0M | $81.3M | ||
| Q3 24 | $-35.3M | $57.7M | ||
| Q2 24 | $-7.2M | $28.9M | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | $33.8M | ||
| Q2 24 | $-7.3M | $17.0M | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | 29.6% | ||
| Q2 24 | -9.9% | 28.3% | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | 21.0% | ||
| Q2 24 | 0.1% | 19.8% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.93× | ||
| Q3 24 | — | 2.06× | ||
| Q2 24 | — | 2.19× | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SVM
Segment breakdown not available.
